Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 8/20 | 0.58 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.58 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.58 |
| ▸ | TPI1 | P60174 | 2/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.38 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.38 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.38 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3429625 | 0.98 | LPAR3 (0.61) | LPAR3LPAR2LPAR1TPI1CSNK2A2 | |
| SCHEMBL837423 | 0.92 | — | — | |
| SCHEMBL1574125 | 0.87 | LPAR3 (0.71) | LPAR3LPAR2LPAR1TPI1CSNK2A2 | |
| SCHEMBL28124639 | 0.84 | LPAR3 (0.76) | LPAR3LPAR2LPAR1CSNK2A2CSNK2B | |
| SCHEMBL27042238 | 0.84 | LPAR3 (0.76) | LPAR3LPAR2LPAR1CSNK2A2CSNK2B | |
| SCHEMBL27042244 | 0.84 | LPAR3 (0.76) | LPAR3LPAR2LPAR1CSNK2A2CSNK2B | |
| SCHEMBL9233772 | 0.84 | LPAR3 (0.76) | LPAR3LPAR2LPAR1CSNK2A2CSNK2B | |
| SCHEMBL6033633 | 0.84 | LPAR3 (0.76) | LPAR3LPAR2LPAR1CSNK2A2CSNK2B | |
| SCHEMBL6851142 | 0.84 | LPAR3 (0.76) | LPAR3LPAR2LPAR1CSNK2A2CSNK2B | |
| Ammonia Solution, Strong SCHEMBL14974533 | 0.81 | LPAR3 (0.73) | LPAR3LPAR2LPAR1CSNK2A2CSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150592-A1 | PHOTOCURABLE CONDUCTIVE BLACK COMPOSITION AND A METHOD FOR FORMING A CURED PRODUCT THEREOF | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT | 2024-05-09 | — | — | US | claimed |
| CN-117986997-A | Photocurable conductive black composition and method for forming cured product thereof | 杜邦电子公司 | 2024-05-07 | — | — | CN | claimed |
| US-20240150592-A1 | PHOTOCURABLE CONDUCTIVE BLACK COMPOSITION AND A METHOD FOR FORMING A CURED PRODUCT THEREOF | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT | 2024-05-09 | — | — | US | disclosed |
| CN-117986997-A | Photocurable conductive black composition and method for forming cured product thereof | 杜邦电子公司 | 2024-05-07 | — | — | CN | disclosed |
| US-11735737-B2 | Binder for electricity storage devices improving dispersibility of conductive assistant | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2023-08-22 | — | — | US | disclosed |
| US-20230212148-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| WO-2023102523-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| EP-4023686-A1 | BINDER FOR ELECTRICITY STORAGE DEVICES IMPROVING DISPERSIBILITY OF CONDUCTIVE ASSISTANT | FUJIFILM Wako Pure Chemical Corporation (JP) | 2022-07-06 | — | — | EP | disclosed |
| US-20220190343-A1 | BINDER FOR ELECTRICITY STORAGE DEVICES IMPROVING DISPERSIBILITY OF CONDUCTIVE ASSISTANT | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2022-06-16 | — | — | US | disclosed |
| US-20220181633-A1 | BINDER FOR ELECTRICITY STORAGE DEVICES | FUJIFILM CORPORATION (JP) | 2022-06-09 | — | — | US | disclosed |
| CN-114270572-A | Binder for electricity storage device | 富士胶片株式会社 | 2022-04-01 | — | — | CN | disclosed |
| CN-113711393-A | Binder for electricity storage device for improving dispersibility of conductive auxiliary agent | 富士胶片和光纯药株式会社 | 2021-11-26 | — | — | CN | disclosed |
| WO-2021039960-A1 | BINDER FOR ELECTRICITY STORAGE DEVICES | 富士フイルム株式会社 | 2021-03-04 | — | — | WO | disclosed |
| WO-2021039959-A1 | BINDER FOR ELECTRICITY STORAGE DEVICES IMPROVING DISPERSIBILITY OF CONDUCTIVE ASSISTANT | 富士フイルム和光純薬株式会社 | 2021-03-04 | — | — | WO | disclosed |
| EP-1793823-B1 | PHOSPHATE CONTAINING PRODRUGS OF SULFONYL HYDRAZINES AS HYPOXIA-SELECTIVE ANTINEOPLASTIC AGENTS | VION PHARMACEUTICALS INC (US) | 2012-08-08 | — | — | EP | disclosed |
| US-20090075945-A1 | Phosphate-bearing prodrugs of sulfonyl hydrazines as hypoxia-selective antineoplastic agents | VION PHARMACEUTICALS, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-7405317-B2 | Phosphate-bearing prodrugs of sulfonyl hydrazines as hypoxia-selective antineoplastic agents | VION PHARMACEUTICALS INC. (US) | 2008-07-29 | — | — | US | disclosed |
| EP-1793823-A2 | SULFONYL HYDRAZINES AS HYPOXIA-SELECTIVE ANTINEOPLASTIC AGENTS | Vion Pharmaceuticals, Inc. (US) | 2007-06-13 | — | — | EP | disclosed |
| US-20060089332-A1 | Phosphate-bearing prodrugs of sulfonyl hydrazines as hypoxia-selective antineoplastic agents | NANOSHIFT, LLC | 2006-04-27 | — | — | US | disclosed |
| WO-2006034266-A2 | SULFONYL HYDRAZINES AS HYPOXIA-SELECTIVE ANTINEOPLASTIC AGENTS | VION PHARMACEUTICALS, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089332-A1 | Phosphate-bearing prodrugs of sulfonyl hydrazines as hypoxia-selective antineoplastic agents | HIF1AN, HIF1A, EGLN3 | LPAR3 2599/4885LPAR2 3338/4885LPAR1 3745/4885 |
| US-20230212148-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | CPSF6, NFATC1, CPSF1 | LPAR3 4747/4885LPAR2 4435/4885LPAR1 4546/4885 |
| US-20090075945-A1 | Phosphate-bearing prodrugs of sulfonyl hydrazines as hypoxia-selective antineoplastic agents | HIF1AN, HIF1A, SLC20A1 | LPAR3 1595/4885LPAR2 2485/4885LPAR1 1782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.